Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 26

1.

Expression of selected angiogenesis-related small microRNAs in patients with abnormally increased secretion of glucocorticoids.

Kawa MP, Sobuś A, Litwińska Z, Osowicz-Korolonek L, Cymbaluk-Płoska A, Stecewicz I, Zagrodnik E, Romanowska H, Walczak M, Syrenicz A, Machaliński B.

Endokrynol Pol. 2019;70(6):489-495. doi: 10.5603/EP.a2019.0061.

PMID:
31909455
2.

Double-Emulsion Copolyester Microcapsules for Sustained Intraperitoneal Release of Carboplatin.

Cymbaluk-Płoska A, Sobolewski P, Chudecka-Głaz A, Wiśniewska E, Łapczuk J, Frankowski M, Droździk M, El Fray M.

J Funct Biomater. 2019 Dec 6;10(4). pii: E55. doi: 10.3390/jfb10040055.

3.

The sFlt-1/PlGF ratio values within the <38, 38-85 and >85 brackets as compared to perinatal outcomes.

Bednarek-Jędrzejek M, Kwiatkowski S, Ksel-Hryciów J, Tousty P, Nurek K, Kwiatkowska E, Cymbaluk-Płoska A, Torbé A.

J Perinat Med. 2019 Sep 25;47(7):732-740. doi: 10.1515/jpm-2019-0019.

PMID:
31339858
4.

Selected features of breast and peritoneal cancers diagnosed in BRCA1 carriers after risk-reducing salpingo-oophorectomy.

Menkiszak J, Chudecka-Głaz A, Cymbaluk-Płoska A, Celewicz A, Kojs Z, Szajda M, Świniarska M, Bedner R, Jurczak A, Celewicz M, Cieszyńska M, Lubiński J, Gronwald J.

Hered Cancer Clin Pract. 2019 Mar 14;17:10. doi: 10.1186/s13053-019-0109-5. eCollection 2019.

5.

The role of lipocalin-2 serum levels in the diagnostics of endometrial cancer.

Cymbaluk-Płoska A, Chudecka-Głaz A, Pius-Sadowska E, Machaliński B, Sompolska-Rzechuła A, Kwiatkowski S, Menkiszak J.

Cancer Biomark. 2019;24(3):315-324. doi: 10.3233/CBM-181942.

6.

Risk Model in Women with Ovarian Cancer Without Mutations.

Cymbaluk-Płoska A, Chudecka-Głaz A, Sompolska-Rzechuła A, Rasinska K, Dubiel P, Menkiszak J.

Open Med (Wars). 2018 Nov 25;13:565-574. doi: 10.1515/med-2018-0084. eCollection 2018.

7.

Could HE4 level measurements during first-line chemotherapy predict response to treatment among ovarian cancer patients?

Chudecka-Głaz A, Cymbaluk-Płoska A, Wężowska M, Menkiszak J.

PLoS One. 2018 Mar 27;13(3):e0194270. doi: 10.1371/journal.pone.0194270. eCollection 2018.

8.

Evaluation of biologically active substances promoting the development of or protecting against endometrial cancer.

Cymbaluk-Płoska A, Chudecka-Głaz A, Jagodzińska A, Pius-Sadowska E, Sompolska-Rzechuła A, Machaliński B, Menkiszak J.

Onco Targets Ther. 2018 Mar 13;11:1363-1372. doi: 10.2147/OTT.S155942. eCollection 2018.

9.

Circulating Serum Level of Visfatin in Patients with Endometrial Cancer.

Cymbaluk-Płoska A, Chudecka-Głaz A, Pius-Sadowska E, Sompolska-Rzechuła A, Machaliński B, Menkiszak J.

Biomed Res Int. 2018 Jan 4;2018:8576179. doi: 10.1155/2018/8576179. eCollection 2018.

10.

Suitability assessment of baseline concentration of MMP3, TIMP3, HE4 and CA125 in the serum of patients with ovarian cancer.

Cymbaluk-Płoska A, Chudecka-Głaz A, Pius-Sadowska E, Machaliński B, Menkiszak J, Sompolska-Rzechuła A.

J Ovarian Res. 2018 Jan 5;11(1):1. doi: 10.1186/s13048-017-0373-9.

11.

Implementation of an enhanced recovery after surgery (ERAS) protocol in a gynaecology department - the follow-up at 1 year.

Nikodemski T, Biskup A, Taszarek A, Albin M, Chudecka-Głaz A, Cymbaluk-Płoska A, Menkiszak J.

Contemp Oncol (Pozn). 2017;21(3):240-243. doi: 10.5114/wo.2017.69589. Epub 2017 Sep 29.

12.

Clinical Relevance of NGAL/MMP-9 Pathway in Patients with Endometrial Cancer.

Cymbaluk-Płoska A, Chudecka-Głaz A, Pius-Sadowska E, Sompolska-Rzechuła A, Chudecka K, Bulsa M, Machaliński B, Menkiszak J.

Dis Markers. 2017;2017:6589262. doi: 10.1155/2017/6589262. Epub 2017 Sep 27.

13.

Clinical importance of serum HE4 and MMP2 levels in endometrial cancer patients.

Cymbaluk-Płoska A, Chudecka-Głaz A, Pius-Sadowska E, Sompolska-Rzechuła A, Machaliński B, Surowiec A, Menkiszak J.

Onco Targets Ther. 2017 Jun 27;10:3169-3175. doi: 10.2147/OTT.S136750. eCollection 2017.

14.

Thrombospondin-I concentrations behavior in plasma of patients with ovarian cancer.

Cymbaluk-Płoska A, Chudecka-Głaz A, Pius-Sadowska E, Machaliński B, Menkiszak J.

Cancer Biomark. 2017 Jul 19;20(1):31-39. doi: 10.3233/CBM-161546.

PMID:
28655131
15.

Ectopic pregnancy treatment by combination therapy.

Cymbaluk-Płoska A, Chudecka-Głaz A, Kuźniak S, Menkiszak J.

Open Med (Wars). 2016 Dec 16;11(1):530-536. doi: 10.1515/med-2016-0091. eCollection 2016.

16.

HE4 Serum Levels in Patients with BRCA1 Gene Mutation Undergoing Prophylactic Surgery as well as in Other Benign and Malignant Gynecological Diseases.

Chudecka-Głaz A, Cymbaluk-Płoska A, Strojna A, Menkiszak J.

Dis Markers. 2017;2017:9792756. doi: 10.1155/2017/9792756. Epub 2017 Jan 15.

17.
18.

New poly(ester-amide) copolymers modified with polyether (PEAE) for anticancer drug encapsulation.

Chudecka-Głaz A, Szczeblińska J, Cymbaluk-Płoska A, Kohn J, El Fray M.

J Microencapsul. 2016 Dec;33(8):702-711. doi: 10.1080/02652048.2016.1228708.

PMID:
27705049
19.

MMP3 in Comparison to CA 125, HE4 and the ROMA Algorithm in Differentiation of Ovarian Tumors.

Cymbaluk-Ploska A, Chudecka-Glaz A, Surowiec A, Pius-Sadowska E, Machalinski B, Menkiszak J.

Asian Pac J Cancer Prev. 2016;17(5):2597-603.

20.

Prophylactic salpingo-oophorectomy in BRCA1 mutation carriers and postoperative incidence of peritoneal and breast cancers.

Menkiszak J, Chudecka-Głaz A, Gronwald J, Cymbaluk-Płoska A, Celewicz A, Świniarska M, Wężowska M, Bedner R, Zielińska D, Tarnowska P, Jakubowicz J, Kojs Z.

J Ovarian Res. 2016 Feb 29;9:11. doi: 10.1186/s13048-016-0220-4.

Supplemental Content

Loading ...
Support Center